» Articles » PMID: 11704586

Interleukin-5 Induces CD34(+) Eosinophil Progenitor Mobilization and Eosinophil CCR3 Expression in Asthma

Overview
Specialty Critical Care
Date 2001 Nov 13
PMID 11704586
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Asthma is characterized by the accumulation of activated T cells and eosinophils within the airway. Eosinophils derive from CD34(+) bone marrow progenitor cells under the influence of hematopoietic growth factors, subsequently migrating to the airways under the cooperative influence of interleukin (IL)-5 and chemokines, including eotaxin. We compared the relative effects of systemic versus local IL-5 on progenitor-cell mobilization and mature eosinophil phenotype by using flow cytometry, following the administration of intravenous (2 microg) or inhaled (15 microg) IL-5 to nine patients with mild asthma. Intravenous IL-5 induced a rapid reduction in circulating eosinophil counts followed by prolonged blood eosinophilia. Both intravenous (p < 0.002) and inhaled (p < 0.05) IL-5 significantly increased CD34(+)/CD45(+) lymphoblastoid eosinophil progenitors. Intravenous IL-5 increased mature eosinophil CCR3 expression from a baseline mean fluorescence intensity (MFI) of 658 +/- 51.7 to 995 +/- 93.2 at 24 h (p < 0.05), but had no effect on interleukin-5 receptor subunit alpha or CD11b expression. Lymphocyte CCR3 MFI was increased by intravenous IL-5 from 38.5 +/- 13.6 at baseline to 73.6 +/- 14.3 at 24 h (p < 0.05). Systemic IL-5 increased circulating eosinophil progenitors, suggesting a key role for systemic IL-5 in eosinophil mobilization. Further, IL-5 causes terminal maturation of the eosinophil by increasing CCR3 expression, potentially affecting CCR3-dependent chemotaxis by eosinophils and lymphocytes.

Citing Articles

Long-term safety of mepolizumab for up to ∼10 years in patients with severe asthma: open-label extension study.

Pavord I, Chan R, Brown N, Howarth P, Gilson M, Price R Ann Med. 2024; 56(1):2417184.

PMID: 39465531 PMC: 11520089. DOI: 10.1080/07853890.2024.2417184.


Regulation of Airway Epithelial-Derived Alarmins in Asthma: Perspectives for Therapeutic Targets.

Hansi R, Ranjbar M, Whetstone C, Gauvreau G Biomedicines. 2024; 12(10).

PMID: 39457624 PMC: 11505104. DOI: 10.3390/biomedicines12102312.


Insight into IL-5 as a Potential Target for the Treatment of Allergic Diseases.

Antosz K, Batko J, Blazejewska M, Gawor A, Sleziak J, Gomulka K Biomedicines. 2024; 12(7).

PMID: 39062104 PMC: 11275030. DOI: 10.3390/biomedicines12071531.


Efficacy and safety of mepolizumab in a Chinese population with severe asthma: a phase III, randomised, double-blind, placebo-controlled trial.

Chen R, Wei L, Dai Y, Wang Z, Yang D, Jin M ERJ Open Res. 2024; 10(3).

PMID: 38770009 PMC: 11103715. DOI: 10.1183/23120541.00750-2023.


Prevalence, incidence and healthcare burden of eosinophilic granulomatosis with polyangiitis in the UK.

Hwee J, Harper L, Fu Q, Nirantharakumar K, Mu G, Jakes R ERJ Open Res. 2024; 10(3).

PMID: 38746859 PMC: 11089387. DOI: 10.1183/23120541.00430-2023.